Study of BMS-986453 in Newly Diagnosed Multiple Myeloma

Part of paid clinical trials in Birmingham, Alabama.

Sponsor
Susan Bal
Study ID
NCT07333261
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
19 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • BMS-986453 — DRUG
    Will be given as a single dose administered by IV infusion.

Study Details

This is a phase 1b study evaluating if BMS-986453 is safe and effective in treating people who have newly diagnosed multiple myeloma after completing initial therapy (induction) when a stem cell transplant is not intended.

Key Dates

Start date
Feb 9, 2026
Status verified
Feb 2026
Primary completion
Dec 31, 2031
Completion
Dec 31, 2041

Study Design

Enrollment
25 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Single dose BMS-986453
    Participants will be treated with fludarabine IV (30 mg/m2/day) and cyclophosphamide IV (300 mg/m2/day) for 3 days prior to BMS-986453 infusion. A single dose of BMS-986453 administered by IV infusion.

Primary Outcome Measure

Number of participants with treatment-related adverse events as assessed by CTCAE v5.0 [ Time Frame: Baseline up to 5 years ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
University of Alabama at BirminghamBirminghamAlabama35294
Susan Bal, MD
[email protected]
2059347645
Luciano J Costa, MD, PhD
[email protected]
Susan Bal, MD (PRINCIPAL_INVESTIGATOR)
Luciano J Costa, MD, PhD (SUB_INVESTIGATOR)
Kelly Godby, MD (SUB_INVESTIGATOR)
Gayathri Ravi, MD (SUB_INVESTIGATOR)
Heidi Worth, MD (SUB_INVESTIGATOR)

Find similar trials in Birmingham, AL

By condition
Multiple myeloma
By specialty
OncologyBlood cancer
By research site
University of Alabama at Birmingham· Birmingham, AL

Related Studies